Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT02694536
Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
- Conditions
- Carcinoma, Non-Small-Cell LungBrain Neoplasms
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 109
- Registration Number
- NCT02655536
- Locations
- 🇨🇳
Department of Oncology, Nationa Taiwan University Hospital, Taipei, Taiwan
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Conditions
- Relapsed Pediatric Solid TumorRefractory Pediatric Solid TumorRelapsed Pediatric AMLRefractory Pediatric AML
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02638428
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 200
- Registration Number
- NCT02633189
- Locations
- 🇮🇹
Ospedale Maggiore, Trieste, Italy
🇮🇹A.O.U. Integrata, Verona, Italy
🇮🇹A.S.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 25
- Registration Number
- NCT02625168
- Locations
- 🇭🇰
Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong
A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 299
- Registration Number
- NCT02595450
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 530
- Registration Number
- NCT02588261
- Locations
- 🇺🇸
Site US10025, Fountain Valley, California, United States
🇺🇸Site US10003, Santa Monica, California, United States
🇺🇸Site US10013, Aventura, Florida, United States
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 341
- Registration Number
- NCT02574078
- Locations
- 🇺🇸
Cancer Care Center, Bismarck, North Dakota, United States
🇺🇸Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸Texas Oncology Cancer Center - Sugar Land, Sugar Land, Texas, United States
IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 12
- Registration Number
- NCT02556593
- Locations
- 🇨🇳
Hui Liu, Guangdong, China
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
- Conditions
- Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 11
- Registration Number
- NCT02535338
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.